Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones

Diabetologia

Volumn 48, Issue 5, 2005, Pages 967-975

  Ionut, V ^a   Hucking, K ^a   Liberty, I F ^a   Bergman, R N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Counter regulation; Glucagon like peptide 1 (GLP 1); Hypoglycaemia; Insulin independent; Portal

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH HORMONE; HORMONE; HYDROCORTISONE; INSULIN; LACTIC ACID;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXPERIMENTAL MODEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HORMONE DETERMINATION; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESPONSE; MALE; MEAL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD GLUCOSE; DOGS; DRUG SYNERGISM; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; PEPTIDE FRAGMENTS; PORTAL VEIN; PROTEIN PRECURSORS;

EID: 20044379258     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1709-3     Document Type: Article

References (43)

1. Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes/Metab Res Rev 18:430-441
2. Nauck M (1999) Is glucagon-like peptide 1 an incretin hormone? Diabetologia 42:373-379
3. Drucker DJ (2001) Mini review: the glucagon-like peptides. Endocrinology 142:521-527
4. Suda K, Takahashi H, Fukase N, Manaka H, Tominaga M, Sasaki H (1989) Distribution and molecular forms of glucagon-like peptide in the dog. Life Sci 45:1793-1798
5. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539
6. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol, Endocrinol Metab 271:E458-E464
7. Kieffer TJ, Mcintosh CHS, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase-IV. Endocrinology 136:3585-3596
8. Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544
9. Holst JJ (1999) Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10:229-235
10. Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase iv in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
11. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A (1996) The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61:149-154
12. Nishizawa M, Nakabayashi H, Kawai K et al. (2000) The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80:14-21
13. Balkan B, Li X (2000) Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol, Regul Integr Comp Physiol 279:R1449-R1454
14. Burcelin R, Da Costa A, Drucker D, Thorens B (2001) Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728
15. Nishizawa M, Moore MC, Shiota M et al. (2003) Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol, Endocrinol Metab 284:E1027-E1036
16. Hevener AL, Bergman RN, Donovan CM (2000) Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. Diabetes 49:8-12
17. Donovan CM, Halter JB, Bergman RN (1991) Importance of hepatic glucoreceptors in sympathoadrenal response to hypoglycemia. Diabetes 40:155-158
18. Hamilton-Wessler M, Bergman RN, Halter JB, Watanabe RM, Donovan CM (1994) The role of liver glucosensors in the integrated sympathetic response induced by deep hypoglycemia in dogs. Diabetes 43:1052-1060
19. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Nijima A (1996) Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol, Endocrinol Metab 34:E808-E813
20. Burcelin R, Dolci W, Thorens B (2000) Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes 49:1635-1642
21. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD (2004) Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol, Endocrinol Metab 287:E75-E81
22. Steil GM, Ader M, Moore DM, Rebrin K, Bergman RN (1996) Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest 97:1497-1503
23. Watanabe RM, Bergman RN (2000) Accurate measurement of endogenous insulin secretion does not require separate assessment of C-peptide kinetics. Diabetes 49:373-382
24. Nauck MA, Niedereichholz U, Ettler R et al. (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, Endocrinol Metab 273:E981-E988
25. Ryan AS, Egan JM, Habener JF, Elahi D (1998) Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2404
26. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
27. Meneilly GS, McIntosh CHS, Pederson RA et al. (2001) Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956
28. Freyse EJ, Becher T, El Hag O, Knospe S, Goke B, Fischer U (1997) Blood glucose lowering and glucagonostatic effects of glucagon-like peptide 1 in insulin-deprived diabetic dogs. Diabetes 46:824-828
29. Sandhu H, Wiesenthal SR, MacDonald PE et al. (1999) Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053
30. Shalev A, Ninnis R, Keller U (1998) Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 49:221-225
31. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266
32. D'Alessio DA, Prigeon RL, Ensinck JW (1995) Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide 1. Diabetes 44:1433-1437
33. Orskov L, Holst JJ, Moller J et al. (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232
34. Toft-Nielsen M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556
35. Larsson H, Holst JJ, Ahren B (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422
36. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43:104-108
37. Freyse EJ, Knospe S, Becher T, El Hag O, Goke B, Fischer U (1999) Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism 48:134-137
38. Zangeneh F, Basu R, Shah P, Arora P, Camilleri M, Rizza RA (2003) Enteral infusion of glucose at rates approximating EGP enhances glucose disposal but does not cause hypoglycemia. Am J Physiol, Endocrinol Metab 285:E280-E286
39. Moore MC, Cardin S, Edgerton DS et al. (2004) Unlike mice, dogs exhibit effective glucoregulation during low-dose portal and peripheral glucose infusion. Am J Physiol, Endocrinol Metab 286:E226-E233
40. Holst JJ, Gromada J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol, Endocrinol Metab 287:E199-E206
41. Nauck MA, Heimesaat MM, Behle K et al. (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
42. Cryer PE (1997) Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin-dependent) diabetes mellitus. Horm Metab Res 29:92-96
43. Flattem N, Igawa K, Shiota M, Emshwiller MG, Neal DW, Cherrington AD (2001) Alpha- and beta cell responses to small changes in plasma glucose in the conscious dog. Diabetes 50:367-375